Main text: 950 2
To the editor:
Diabetes mellitus (DM) and tuberculosis (TB) are major global public health priorities (1, 2) .
Many studies have assessed the relationship between DM and active TB disease (3) . Data on the effect of DM on the risk of latent TB infection (LTBI) are more limited. A recent systematic review identified one cohort study, with an adjusted risk ratio of 4.40 (95% CI 0.50-38.55), and 12 cross-sectional studies which generated a pooled adjusted odds ratio of 1.18 (95% CI 1.06-1.30) (4).
The PREDICT (Prognostic Evaluation of Diagnostic IGRAs Consortium) study was a prospective, multi-site UK cohort study aiming to evaluate the predictive values of interferon gamma release assays (IGRAs) for the development of active TB among recent entrants to the UK from high-burden countries and contacts of active TB cases ("contacts"). PREDICT was approved by the Brent Research Ethics Committee (reference 10/H0717/14) and is registered on clinicaltrials.gov (NCT01162265). In this study, we use baseline data from PREDICT to investigate the association between DM and LTBI.
Recruitment took place between January 2011 and July 2015. After giving informed consent, participants completed a questionnaire and provided blood samples for IGRAs. Participants with evidence of active TB were excluded. The main exposure of interest in this secondary analysis was a self-reported history of DM. Data were also collected on the method of DM control used. The outcome of interest was LTBI, defined as a positive result for either or both of the two commercially available IGRAs, Quantiferon-TB Gold In-Tube (QFT-GIT -Qiagen) and TSpot.TB (Oxford Immunotec, Abingdon, UK). Participants with no valid IGRA results were excluded from this analysis. Other covariates on which data were collected are described in the Supplement.
Binomial regression with a log link was used to estimate crude and adjusted prevalence ratios (PRs) and 95% CIs for the relationship between DM and LTBI (5). Age and sex were treated as a priori confounders. A causal diagram of the relationships between potential confounders and outcomes using directed acyclic graphs, interpreted using dagitty.net (6) ( Figure S1 ), was used to identify the minimum set of other covariates required for adjustment. P values were derived from likelihood ratio tests. We assessed potential interactions between DM and age (3) and DM and ethnicity (7), as observed for active TB (3, 7) . All analyses used a complete-case approach. We conducted sensitivity analyses: 1) adjusting for age as a continuous variable using fractional polynomials (8) 9157 participants were included in the analysis (Table 1, Table S2 , Figure S2 ). 756 participants (8.3%) reported having diabetes, of whom 535 provided information about how they controlled the condition: 409 taking medication, 55 on insulin, 20 using both insulin and other medication(s) and 51 through monitoring and/or diet only.
Prevalence of a positive IGRA was 31.5% and 27.3% amongst those with and without DM, respectively (Table 1: unadjusted PR=1.15, 95% CI 1.03-1.29, p=0.012). Characteristics associated with a positive IGRA included increasing age, male sex, being born outside the UK, being a contact, having had a previous TB diagnosis or previous contact with a TB patient, and immunosuppression (Table 1) . IGRA positivity varied by ethnicity, being highest in the Black African ethnic group and lowest amongst Black Caribbean participants. There was no evidence that having a positive IGRA was associated with previous BCG vaccination, HIV status, BMI, smoking, or social risk factors (Table 1) . Complete covariate data were available for 8336 participants (91.0% of the included participants). Adjusting for sex, age group, ethnicity, immunosuppression and BMI, the PR for the association between DM and LTBI was 1.15 (95% CI 1.02-1.30, p=0.025, Table S2 ).
There was no evidence of interaction between DM and age group (p=0.22) and weak evidence of interaction between DM and ethnicity (p=0.055, Table S3 ). Sensitivity analyses produced similar results, although the PR increased to 1.29 (95% CI 1.09-1.52, p=0.002) when analysis was restricted to contacts (Table S4) .
Our results are likely to be generalisible to migrants and contacts in the UK (although there were some differences between participants included and excluded from the analysis [ Table   S1 ]), but perhaps not to other settings with different distributions of risk factors including country of birth and ethnicity. We used both of the commercially available IGRAs, and conducted a sensitivity analysis restricted to participants with concordant results, providing additional certainty regarding the diagnosis of LTBI. Limitations of the study include the self- 
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